8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Methotrexate

Essential medicine status

ATC codes: L01BA01

Indication: Osteosarcoma of bone and articular cartilage of unspecified sites


INN: Methotrexate

Medicine type: Chemical agent

List type: Complementary

Formulations:
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)

EML status history:
First added in 2015 (TRS 994)

Sex: All

Age: Also recommended for children

Therapeutic alternatives:
The recommendation is for this specific medicine

Patent information:
Patents have expired in most jurisdictions
Read more about patents.

Tags: Cancer

Wikipedia: Methotrexate

DrugBank: Methotrexate

Summary of evidence and Expert Committee recommendations:
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methotrexate on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for osteosarcoma is attached.